We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunogenicity and safety of COVID-19 vaccines in actively treated solid cancer patients.
- Authors
Yae Jee Baek; Ki Hyun Lee; Eun Hwa Lee; Se Ju Lee; Jinnam Kim; Jung Ho Kim; Su Jin Jeong; Nam Su Ku; Jun Yong Choi; Joon-Sup Yeom; Jin Young Ahn; Minkyu Jung
- Abstract
배경 Patients with cancer are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination including booster doses. We aimed to assess the immunogenicity and safety of COVID-19 vaccination and analyze factors associated with the immunogenicity of the vaccine among actively treat- ed solid cancer patients (CPs) in Korea. 방법 A prospective cohort was established among CPs undergoing anticancer treatment in a tertiary hospital in Korea. Patients in this cohort had no history of previous SARS-CoV-2 infection confirmed by baseline serological testing and received at least one dose of COVID-19 vaccine in accordance with the vaccine strategy. Blood samples were collected before prime vaccination, and beyond 2 weeks for each dose of vaccine administration. Spike (S)- specific IgG antibodies were analyzed on each sample. Adverse events (AEs) within 7 days following each vaccine dose were collected. Data from age-matched healthcare workers (HCWs) recruited into a separate study are included as a comparison cohort. 결과 Between April 2021 to November 2021, we enrolled 134 CPs; 118 were eligible for analysis. The demographics of CPs and HCWs are described in Table 1. CPs were treated with cytotoxic agents (78.8%), immunotherapy (16.9%), target therapy (18.6%), and others (5.9%), that were given either alone or in combinations. The rate of seroconversion after 1st vaccination in CPs was significantly lower than in HCWs (p value=0.001), however, all CPs and HCWs revealed seroconversion after 2nd vaccination (Figure 1). Antibody response was significantly increased following each dose of vaccination in both CPs and HCWs (Figure 2A). The geometric mean titer (GMT) of S-specific IgG antibodies after 2nd vaccination in CPs who received a primary set of adenovirus vector vaccine were significantly lower than that in HCWs, whereas CPs who received a primary set of mRNA vaccines showed comparable GMT with HCWs after 2nd vaccination (Figure 2B). After the 3rd vaccination, there was no statistical difference in GMT of S-specific antibodies between CPs and HCWs regardless of the type of primary vaccine. In age-matched analysis between good responders (defined as those with higher antibody titers after 2nd vaccination than the mean of age-stratified HCW cohort) and poor responders (defined as those with lower titers) among CPs, there was no significant difference in other factors including the type of vaccine, cancer or anticancer treatment except lower leukocyte counts in poor responders treated with cytotoxic agents. The incidence and severity of AEs were similar between CPs and HCWs without any severe vaccine-related AEs. 결론 Patients with solid cancer had delayed antibody response compared to HCWs after the 1st vaccination but all CPs showed seroconversion after 2nd vaccination. Antibody responses similar to that of HCWs were achieved after the 3rd dose of vaccination in actively treated CPs in this study.
- Subjects
SOUTH Korea; ADENOVIRUS diseases; VACCINE safety; IMMUNE response; COVID-19 vaccines; MEDICAL personnel; HIV seroconversion; BOOSTER vaccines
- Publication
Infection & Chemotherapy, 2022, Vol 54, pS208
- ISSN
2093-2340
- Publication type
Article